Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial.

  • 2025-12-25
  • Medicina (Kaunas, Lithuania) 62(1)
    • Janvier Youovop
    • Guy Takuissu
    • Régine Minoue
    • Felix Nwang
    • Maryam Adegboyega
    • Crista Arrey
    • Inelle Makamwe
    • Julius Oben

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 248
Population
248 adults (126 women and 122 men; mean age 41.3 ± 0.3 years; BMI 25-34.9 kg/m^2)
Methods
16-week, randomized, double-blind, placebo-controlled trial; 400 mg D. glomerata extract, 300 mg C. quadrangularis extract, semaglutide (dose-escalated from 3 mg to 14 mg), or placebo, administered once daily
Blinding
Double-blind
Duration
16 weeks
Funding
Unclear
  • Large Human Trial
Background and Objectives: Dichrostachys glomerata and Cissus quadrangularis, two species traditionally used in Cameroon, are recognized for their weight-reducing potential. This study examined the effects of standardized extracts of these botanicals on glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase-4 (DPP-4), and key metabolic outcomes in individuals with excess body weight. Materials and Methods: In this 16-week, randomized, double-blind, placebo-controlled trial, 248 adults (126 women and 122 men; mean age 41.3 ± 0.3 years; BMI 25-34.9 kg/m2) were assigned to receive 400 mg D. glomerata extract (DGE), 300 mg C. quadrangularis extract (CQE), semaglutide (dose-escalated from 3 mg to 14 mg), or placebo, administered once daily. These are all standard clinical regimens. Primary assessments included changes in GLP-1 levels and DPP-4 activity. Secondary evaluations included body composition, caloric intake, satiety response, fasting glucose levels, and lipid profiles. Results: Participants receiving DGE or CQE displayed notable elevations in circulating GLP-1 (+38.6 pg/mL and +42.2 pg/mL, respectively; p < 0.01) and significant reductions in DPP-4 activity (-15.3% and -17.8%; p < 0.01) compared with placebo. Both extracts produced substantial improvements in body weight (-5.2% and -5.8%), body fat (-10.3% and -10.9%), energy intake (-16.2% and -17.5%), and satiety (+25.6% and +27.4%) (p < 0.01). Significant changes in fasting glucose and serum lipid levels were also observed (p < 0.05). These responses are comparable to those of semaglutide. Moreover, GLP-1 increments showed strong negative correlations with body fat percentage (r = -0.91 to -0.92; p < 0.001) and DPP-4 activity (r = -0.97 to -0.98; p < 0.001). Conclusions: Supplementation with D. glomerata and C. quadrangularis extracts enhanced GLP-1 secretion and reduced DPP-4 activity, yielding significant benefits for body composition and metabolic parameters. These findings indicate that both botanicals are promising natural agents for managing obesity through incretin-based mechanisms.

Research Insights

Back to top